Acrivon Therapeutics upgraded to Buy from Neutral at Ladenburg
PremiumThe FlyAcrivon Therapeutics upgraded to Buy from Neutral at Ladenburg
26d ago
Acrivon reports data from ongoing ACR-368 registrational intent Phase 2 study
Premium
The Fly
Acrivon reports data from ongoing ACR-368 registrational intent Phase 2 study
27d ago
Acrivon Therapeutics to host investor event on Phase 2 data of ACR-368
Premium
The Fly
Acrivon Therapeutics to host investor event on Phase 2 data of ACR-368
1M ago
Acrivon Therapeutics price target raised to $22 from $20 at H.C. Wainwright
PremiumThe FlyAcrivon Therapeutics price target raised to $22 from $20 at H.C. Wainwright
5M ago
Acrivon Therapeutics reports Q1 EPS (73c), consensus (84c)
Premium
The Fly
Acrivon Therapeutics reports Q1 EPS (73c), consensus (84c)
5M ago
Acrivon Therapeutics downgraded to Neutral from Buy at Ladenburg
Premium
The Fly
Acrivon Therapeutics downgraded to Neutral from Buy at Ladenburg
6M ago
Acrivon Therapeutics price target raised to $30 from $26 at Piper Sandler
PremiumThe FlyAcrivon Therapeutics price target raised to $30 from $26 at Piper Sandler
6M ago
Acrivon Therapeutics price target raised to $17 from $14 at JMP Securities
Premium
The Fly
Acrivon Therapeutics price target raised to $17 from $14 at JMP Securities
6M ago
Acrivon Therapeutics Reports Breakthrough Results and Solid Finances
Premium
Company Announcements
Acrivon Therapeutics Reports Breakthrough Results and Solid Finances
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100